An van Es-Johansson, M.D.
PLUS THERAPEUTICSAbout An van Es-Johansson, M.D.
Dr. An van Es-Johansson, age 65, has served on the Plus Therapeutics (PSTV) Board since 2020 and is an independent director under Nasdaq and SEC rules . She is a physician (M.D., Erasmus University, Rotterdam) with extensive pharma leadership experience, including CMO and Senior Advisor roles, and brings deep medical and rare-disease expertise to the Board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| AlzeCure Pharma | Chief Medical Officer; Senior Advisor | Sep 2018–Mar 1, 2021; Senior Advisor from Mar 2021 | Alzheimer’s focus; executive leadership |
| Sinfonia AB | Senior Advisor | Since 2021 | Neuroscience focus |
| Sobi (Swedish Orphan Biovitrum) | Executive roles; VP & Head EMENAR Medical Affairs | 2005–2018; VP Mar 2013–Jan 2018 | Specialty care; partner products; medical affairs leadership |
| Roche; Pharmacia; Eli Lilly; Active Biotech; BioStratum | Various leadership positions | Prior to 2005 | Large-cap pharma and biotech leadership exposure |
| Uppsala Bio | Scientific Advisory Board Member | 2004–2016 | Industry/science interface |
External Roles
| Organization | Role | Tenure |
|---|---|---|
| Savara, Inc. (Nasdaq: SVRA) | Director | Current |
| Lumos Pharma, Inc. (Nasdaq: LUMO) | Director | Current |
| Agendia BV (Private) | Director | Current |
| BioInvent International AB (OMX: BINV) | Director | Jun 2016–Feb 2021 |
| AlzeCure AB (OMX: ALZCUR) | Director | 2017–2020 |
| Medivir AB (OMX: MVIR) | Director | 2019–2022 |
| IRLAB AB (OMX: IRLAB) | Director | May 2022–Feb 2023 |
Board Governance
- Committee assignments: Audit Committee member; Nominating & Corporate Governance Committee member and Chair; not on Compensation Committee .
- Independence: Board determined she is independent; all standing committees are fully independent .
- Attendance and engagement: In 2024, the Board met 8 times and no director attended fewer than 75% of Board and applicable committee meetings; executive sessions of independent directors were held at each regular Board meeting (four in 2024) . Directors (other than Robert Lenk and Greg Petersen) attended the 2024 Annual Meeting .
- Risk oversight: As Nominating & Governance Chair, she oversees Board independence, conflicts, and CEO succession; Audit Committee covers accounting, reporting, and cybersecurity .
- Anti-hedging/pledging policies are in place, aligning directors with stockholders .
Fixed Compensation
| Component | Annual Amount (USD) | Notes |
|---|---|---|
| Board of Directors – Annual Retainer | $40,000 | Approved 2024; expected same in 2025 |
| Audit Committee – Member Retainer | $7,500 | |
| Compensation Committee – Member Retainer | $5,000 | |
| Nominating & Corporate Governance – Member Retainer | $5,000 | |
| Nominating & Corporate Governance – Chair Add’l Retainer | $10,000 | Chair role held by Dr. van Es-Johansson |
| Non-Employee Director | Fees Earned (USD) | Option Awards (USD, ASC 718 FV) | Total (USD) |
|---|---|---|---|
| An van Es-Johansson, M.D. | $57,500 | $9,167 | $66,667 |
Performance Compensation
| Award Type | Grant Date | Quantity (Options) | Price or Grant-Date Inputs | Vesting |
|---|---|---|---|---|
| Director Option Grant | Feb 22, 2024 | 2,250 | ASC 718 FV basis; closing price on grant date | Service-based (director tenure) |
| Director Option Grant | Sep 11, 2024 | 3,650 | ASC 718 FV basis; closing price on grant date | Service-based (director tenure) |
| Director Stock Option (Right to Buy) | Feb 18, 2025 | 40,122 | $1.18 per option; Form 4 | Service-based (Form 4) |
| Director Stock Option (Right to Buy) | Aug 13, 2025 | 297,794 | $0.5744 per option; Form 4 | Service-based (Form 4) |
- Plan governance features: No single-trigger vesting on change in control; no liberal change-in-control definition; repricing prohibited without stockholder approval; robust clawback; non-employee director total annual comp cap $500,000 ($700,000 in initial year) .
- Performance metrics: None disclosed for director awards; vesting is service-based .
Other Directorships & Interlocks
- Current public company boards: Savara (SVRA), Lumos Pharma (LUMO) .
- No related-party transactions involving Dr. van Es-Johansson are disclosed; the Nominating & Governance Committee oversees independence and conflicts, and Audit Committee reviews related person transactions under SEC rules .
Expertise & Qualifications
- M.D. from Erasmus University; extensive medical and pharmaceutical industry leadership across large pharma and rare-disease companies; experience on numerous public and private boards internationally .
- Board qualification emphasis: medical knowledge and pharma industry experience cited as core credentials for Board service .
Equity Ownership
| Holder | Beneficial Ownership (Shares) | % of Outstanding | Notes |
|---|---|---|---|
| An van Es-Johansson, M.D. | 26,750 | <1% | Footnote indicates these are unvested options vesting within 60 days of June 18, 2025 |
| Option Awards Outstanding (as of Dec 31, 2024) | 5,900 | — | Aggregate options outstanding as of 12/31/2024 |
- Shares pledged as collateral: Not disclosed (anti-hedging/pledging policies adopted) .
- Post-transaction ownership snapshots from Form 4:
- Feb 26, 2024 filing: 2,250 options, price $2.03; post-transaction securities owned 2,250 .
- Sep 12, 2024 filing: 3,650 options, price $1.26; post-transaction securities owned 3,650 .
- Feb 20, 2025 filing: 40,122 options, price $1.18; post-transaction securities owned 40,122 .
- Aug 15, 2025 filing: 297,794 options, price $0.5744; post-transaction securities owned 297,794 .
Insider Trades (Form 4 Summary)
| Transaction Date | Filing Date | Type | Quantity | Price | Post-Transaction Securities Owned | Security | Link |
|---|---|---|---|---|---|---|---|
| 2024-02-22 | 2024-02-26 | A (Award) | 2,250 | 2.03 | 2,250 | Stock Option (Right to Buy) | |
| 2024-09-11 | 2024-09-12 | A (Award) | 3,650 | 1.26 | 3,650 | Stock Option (Right to Buy) | |
| 2025-02-18 | 2025-02-20 | A (Award) | 40,122 | 1.18 | 40,122 | Stock Option (Right to Buy) | |
| 2025-08-13 | 2025-08-15 | A (Award) | 297,794 | 0.5744 | 297,794 | Stock Option (Right to Buy) |
Governance Assessment
- Strengths: Independent director; Chair of Nominating & Corporate Governance, directly overseeing independence/conflicts and CEO succession ; active committee service on Audit ; strong attendance and engagement practices; anti-hedging/pledging policy; robust equity-plan governance (no single trigger, no repricing, clawback) .
- Alignment: Director compensation is modest and includes equity options that are service-based; beneficial ownership remains <1%, but recurring equity grants suggest increasing skin-in-the-game over time .
- Shareholder sentiment: All nominees, including Dr. van Es-Johansson, were re-elected at the 2025 AGM; advisory say-on-pay passed with 16.7M votes for vs 0.86M against (broker non-votes 10.29M) .
- Potential risks/RED FLAGS:
- Multiple outside public boards (SVRA, LUMO) and prior extensive board service may pose time-commitment considerations, but no related-party conflicts are disclosed and independence affirmed .
- No hedging/pledging allowed and no option repricings permitted under current plan, reducing typical alignment risks .
Overall, Dr. van Es-Johansson’s governance profile is solid: independent, committee leadership on Nominating & Governance, and Audit participation. Compensation structure is conventional for small-cap biotech (cash retainers plus service-based options), with plan-level safeguards that support investor confidence .